摘要
幽门螺杆菌(helicobacter pylori,Hp)感染与上消化道的炎症、溃疡及恶性肿瘤密切相关。然而,随着对常用抗生素耐药率的逐渐增加,现有根除方案疗效显著下降,亟待探索具有更高根除率的方案。伏诺拉生是一种新型的钾离子竞争性酸阻滞剂(potassium⁃competitive acid blockers,P⁃CABs),抑酸作用强且持久,在临床实践中显示出对Hp尤其是耐药菌株良好的根除效果。本文就目前伏诺拉生用于Hp治疗的作用机制、疗效、研究现状以及安全性进行了总结,旨在为伏诺拉生用于治疗Hp感染的推广应用提供参考。
Helicobacter pylori(Hp)infection is closely associated with inflammation,ulceration and malignancy in the upper gastrointestinal tract.However,with the progressive increase in resistance to commonly used antibiotics,the efficacy of existing eradication regimens has significantly decreased,and there is an urgent need to explore regimens with higher eradication rates.Vonoprazan is a novel potassium⁃competitive acid blockers(P⁃CABs)with strong and long⁃lasting acid⁃suppressive effects,and has shown good eradication effects against Hp,especially drug⁃resistant strains,in clinical practice.This article summarizes the current mechanism of action,efficacy,current status of research and safety of vonoprazan for Hp treatment,aiming to provide a reference for the promotion of vonoprazan for the treatment of Hp infection.
作者
张苑
朱晏
刘治恺
谢玥
王新颖
ZHANG Yuan;ZHU Yan;LIU Zhikai;XIE Yue;WANG Xinying(The Second Clinical Medical College of South-ern Medical University,Guangzhou 510515,China;不详)
出处
《实用医学杂志》
CAS
北大核心
2021年第24期3218-3222,共5页
The Journal of Practical Medicine
